Arlo-cel Phase I Data in Refractory Myeloma
Peer-reviewed Phase I results for arlocabtagene autoleucel (arlo-cel; BMS-986393; CC-95266), an autologous GPRC5D-directed CAR-T therapy, show clinically meaningful activity in 84 heavily pretreated patients with relapsed or refractory multiple myeloma. Overall response was 87%,…
